Comment
doi: 10.2353/ajpath.2010.100200.
Epub 2010 Apr 15.
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation
Affiliations
- PMID: 20395429
- PMCID: PMC2877822
- DOI: 10.2353/ajpath.2010.100200
Item in Clipboard
Comment
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation
Am J Pathol.
2010 Jun.
Abstract
This commentary discusses the non-immune effects of fingolimod on neuroimmunological diseases.
Comment on
-
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.Am J Pathol. 2010 Jun;176(6):2682-94. doi: 10.2353/ajpath.2010.091234. Epub 2010 Apr 22. Am J Pathol. 2010. PMID: 20413685 Free PMC article.
Similar articles
-
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Neurology. 2011. PMID: 21339487 Review.
-
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.Pharmacol Ther. 2008 Jan;117(1):77-93. doi: 10.1016/j.pharmthera.2007.08.005. Epub 2007 Sep 8. Pharmacol Ther. 2008. PMID: 17961662 Review.
-
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.Am J Pathol. 2010 Jun;176(6):2682-94. doi: 10.2353/ajpath.2010.091234. Epub 2010 Apr 22. Am J Pathol. 2010. PMID: 20413685 Free PMC article.
-
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].Yao Xue Xue Bao. 2012 Jan;47(1):7-17. Yao Xue Xue Bao. 2012. PMID: 22493799 Review. Chinese.
-
Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.Prog Drug Res. 2008;66:361, 363-81. doi: 10.1007/978-3-7643-8595-8_8. Prog Drug Res. 2008. PMID: 18416311 Review.
Cited by
-
S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling.J Cell Mol Med. 2018 Jun;22(6):3159-3166. doi: 10.1111/jcmm.13596. Epub 2018 Mar 13. J Cell Mol Med. 2018. PMID: 29536648 Free PMC article.
-
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.CNS Drugs. 2011 Jan;25(1):37-52. doi: 10.2165/11539820-000000000-00000. CNS Drugs. 2011. PMID: 21128693 Review.
References
-
- Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, (FREEDOMS Study Group) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. - PubMed
-
- Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, (TRANSFORMS Study Group) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415. - PubMed
-
- Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8:1295–1301. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
